Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Telehealth revenue models, multi-year platform investments, and value-based care contracts make American Well Corporation’s disclosures dense reading. If you have ever searched “American Well SEC filings explained simply” or wondered how board decisions affect the hybrid-care roadmap, you know that a single footnote in the 10-K can change your valuation thesis. Add insider moves and sudden 8-K announcements and the research pile grows quickly.
Our SEC Filings hub removes that friction. The moment EDGAR posts a new document—whether it is an “American Well quarterly earnings report 10-Q filing” or an “American Well 8-K material events explained”—our system flags it, then feeds it to Stock Titan’s AI engine. You receive concise overviews, key metric extractions, and contextual links, so “understanding American Well SEC documents with AI” takes minutes, not late nights. Need to monitor “American Well insider trading Form 4 transactions”? We stream “American Well Form 4 insider transactions real-time” and highlight option grants, automatic sales, and beneficial-owner changes in plain language.
Investors use this page to drill into specifics that drive telehealth economics. The “American Well annual report 10-K simplified” section outlines segment revenue for virtual primary care, platform licensing, and professional services. Each “American Well earnings report filing analysis” tracks visit volumes, payer mix, and margin trends across the care continuum. A dedicated tab surfaces “American Well proxy statement executive compensation” so you can compare stock awards to clinical-outcome targets. Practical use cases include spotting “American Well executive stock transactions Form 4” before earnings calls, mapping deferred revenue shifts across quarters, and following R&D spend tied to strategic partnerships. All filings stay in one place, updated in real time, with AI-powered summaries, expert notes, and full original PDFs ready for deep dives.
Simulations Plus, Inc. (SLP) has filed a Form 144 indicating the intent to sell up to 60,000 common shares through Morgan Stanley Smith Barney on or after 01 July 2025. The shares were originally acquired on 01 July 1996 and are classified as “Founders Shares.” At the filing’s stated aggregate market value of $1,047,000, the implied price is roughly $17.45 per share. With 20,111,045 shares outstanding, the proposed sale represents approximately 0.3 % of total shares.
The filer has already disposed of 40,000 shares during the past three months under Rule 10b5-1 trading plans, generating $1.21 million in gross proceeds. No adverse information about the company is disclosed in the notice, as required by Rule 144 representations.
While the transaction size is modest relative to the company’s capitalization, continued insider selling—particularly of founder-level holdings—can be viewed cautiously by investors because it may signal portfolio diversification or changing insider sentiment. However, because the percentage of shares is small and the sale is pre-planned under Rule 10b5-1, the filing is unlikely to materially affect Simulations Plus’ near-term operations or financial position.
Netflix, Inc. (NFLX) has filed a Form 144 disclosing the proposed sale of 290 common shares with an aggregate market value of $388,347.70. The shares are expected to be sold on or about July 1, 2025 on the NASDAQ through Morgan Stanley Smith Barney LLC – Executive Financial Services. The seller is identified in the accompanying tables as Strive Masiyiwa, who previously sold 1,002 shares for $1,126,508.52 on May 12, 2025 under a Rule 10b5-1 trading plan.
The shares to be sold represent less than 0.0001% of Netflix’s approximately 425.7 million shares outstanding, indicating a de minimis impact on the company’s capital structure. Rule 144 filings are routine disclosures that allow insiders to sell restricted or control securities in compliance with SEC regulations. The use of a pre-arranged 10b5-1 plan suggests the sale was scheduled in advance, mitigating concerns of trading on undisclosed information.
Key details
- Seller: Strive Masiyiwa (Netflix board member)
- Shares to be sold: 290
- Planned sale date: 07/01/2025
- Broker: Morgan Stanley Smith Barney LLC
- Previous sales: 1,002 shares on 05/12/2025 for $1.13 million
Given the small size of the transaction relative to Netflix’s market capitalization, the filing is not expected to have a material financial impact, but investors may monitor insider activity for sentiment signals.
Warby Parker Inc. (NYSE: WRBY) has filed a Form 144 indicating an insider’s intent to sell common shares. The notice covers the proposed sale of 50,000 shares—acquired through previously exercised stock options on 11 November 2017—via Morgan Stanley Smith Barney LLC. At the most recent reference price, the transaction is valued at approximately $1.10 million. The filer plans to execute the trade on or about 1 July 2025. Warby Parker reports 104,502,616 shares outstanding, so the sale represents roughly 0.05 % of the float. No other sales by the same party have occurred in the prior three-month period, and the filer attests to possessing no undisclosed material adverse information. Because Form 144 filings merely provide advance notice and do not guarantee execution, the actual sale may vary in timing or size.
For investors, the event is typically viewed as routine liquidity management rather than an outsized insider exit, given the limited share count and negligible dilution effect. Nonetheless, insider intentions can act as a market signal that warrants monitoring alongside other corporate developments.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
What industry does American Well Corp operate in?
How does American Well generate revenue?
What types of care services are supported by the platform?
Who are the primary clients of American Well Corp?
What makes American Well's platform unique?
How does American Well contribute to patient care?
How does the company stay ahead in the competitive telehealth space?
What distinguishes hybrid care in American Well's approach?
